Clinical Trials
4 trialsNCT07083687 2025-07-24
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
Hunan Cancer Hospital
Phase 2 Not yet recruiting
NCT05948462 2023-12-13
NSCLC
SCRI Development Innovations, LLC
Phase 2 Withdrawn
NCT04292119 2021-03-10
Lorlatinib Combinations in Lung Cancer
Massachusetts General Hospital
Phase 1/2 Unknown
NCT02927340 2021-03-09
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
Massachusetts General Hospital
Phase 2 Unknown